ZCM
PVLA

Zebra Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Zebra Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-125
Closed -$36K – 289
2019
Q4 		$36K Buy
+125
New +$34.7K 0.03% 287

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Zebra Capital Management's PVLA Position: Q1 2020 in Review

Zebra Capital Management sold out of Palvella Therapeutics (PVLA) in Q1 2020, closing a stake of 125 shares — an estimated $36K sold.

Zebra Capital Management first reported a position in PVLA in Q4 2019 and held it in 1 quarter. The position peaked at $36K in Q4 2019. 95 funds tracked by Wall St. Rank hold PVLA as of Q1 2020.

  • Zebra Capital Management reported no remaining Palvella Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Zebra Capital Management sold 125 Palvella Therapeutics shares in Q1 2020, an estimated $36K.
  • Zebra Capital Management first reported a position in Palvella Therapeutics in Q4 2019 and held it in 1 quarter.
  • Zebra Capital Management's Palvella Therapeutics position peaked at $36K in Q4 2019.
  • 95 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2020.

Based on Zebra Capital Management's 13F filing for Q1 2020, filed 15 May 2020.